The cannabinoid receptor agonist WIN55.212 reduces consequences of status epilepticus in rats

Neuroscience. 2016 Oct 15:334:191-200. doi: 10.1016/j.neuroscience.2016.08.004. Epub 2016 Aug 9.

Abstract

An acute brain insult can cause a spectrum of primary and secondary pathologies including increased risk for epilepsy, mortality and neurodegeneration. The endocannabinoid system, involved in protecting the brain against network hyperexcitability and excitotoxicity, is profoundly dysregulated by acute brain insults. We hypothesize that post-insult dysregulation of the endocannabinoid signaling may contribute to deleterious effects of an acute brain injury and potentiation of endocannabinoid transmission soon after an insult may reduce its pathological outcomes. Effects of an acute post-insult administration of the endocannabinoid receptor agonist WIN55,212-2 on early seizure occurrence, animal mortality and hippocampal cell loss were studied in the lithium-pilocarpine status model. A single dose of WIN55,212-2 (5mg/kg) administered four hours after the end of status epilepticus (SE) reduced the incidence of early seizures during the first two post-SE days though did not change their duration and latency. Brief 4-6-Hz spike-wave discharges appeared de novo in the latent post-SE period and the acute administration of WIN55,212-2 also reduced the incidence of the epileptiform events. A single dose of WIN55,212-2 administered soon after SE improved survival of animals and reduced cell loss in the dentate hilus but did not prevent appearance of spontaneous recurrent seizures in the chronic period. Thus, a brief pharmacological stimulation of the endocannabinoid system soon after a brain insult exerts beneficial effects on its pathological outcome though does not prevent epileptogenesis.

Keywords: endocannabinoid system; epilepsy; mortality; neurodegeneration; spike–wave discharges; status epilepticus.

MeSH terms

  • Animals
  • Anticonvulsants / pharmacology*
  • Benzoxazines / pharmacology*
  • Cannabinoid Receptor Agonists / pharmacology*
  • Dentate Gyrus / drug effects
  • Dentate Gyrus / pathology
  • Dentate Gyrus / physiopathology
  • Disease Models, Animal
  • Electrocorticography
  • Lithium Compounds
  • Male
  • Morpholines / pharmacology*
  • Naphthalenes / pharmacology*
  • Neurons / drug effects
  • Neurons / pathology
  • Neurons / physiology
  • Neuroprotective Agents / pharmacology
  • Pilocarpine
  • Rats, Wistar
  • Seizures / drug therapy
  • Seizures / pathology
  • Seizures / physiopathology
  • Status Epilepticus / drug therapy*
  • Status Epilepticus / pathology
  • Status Epilepticus / physiopathology
  • Survival Analysis

Substances

  • Anticonvulsants
  • Benzoxazines
  • Cannabinoid Receptor Agonists
  • Lithium Compounds
  • Morpholines
  • Naphthalenes
  • Neuroprotective Agents
  • Pilocarpine
  • (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone